EU/3/08/564: Orphan designation for the treatment of cystic fibrosis

Avian polyclonal IgY antibody

Table of contents

Overview

On 23 September 2008, orphan designation (EU/3/08/564) was granted by the European Commission to Immunsystem I.M.S. AB, Sweden, for avian polyclonal IgY antibody against Pseudomonas aeruginosa for the treatment of cystic fibrosis.

Key facts

Active substance
Avian polyclonal IgY antibody
Intented use
Treatment of cystic fibrosis
Orphan designation status
Positive
EU designation number
EU/3/08/564
Date of designation
23/09/2008
Sponsor
Immunsystem I.M.S. AB
Dag Hammarskjölds väg 26
751 83 Uppsala
Sweden
Telephone: + 46 18 538 909
Telefax: + 46 18 538 997
E-mail: info@immunsystem.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating